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ESMO Open P. Hofman et al.Background: This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories
orientated toward the diagnosis of thoracic diseases.
Materials and methods: A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire
requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking,
the workload, the associated research into COVID-19, and the organization of education and training during the COVID-
19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019.
Results: Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety
procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31%
(range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and
41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the
laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of
study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples.
Conclusions: The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included
in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to
better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new
wave of infection occurring in Europe.
Key words: COVID-19, pathology, biosafety, lung cancer, activityINTRODUCTION
After the initial emergenceof the infection in China in early 2020,
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) virus spread to Europe in February 2020, first to Italy and then
rapidly inMarch-April 2020 to all European countries, notably to
Spain, France, Belgium and the United Kingdom.1-3 None of the
countries of the EuropeanUnionwere spared infection, andasof
March/May 2020, Europe was declared as the epicenter of the
world pandemic (https://www.euro.who.int/en/health-topics/
health-emergencies/coronavirus-covid-19/novel-coronavirus-
2019-ncov). The contagiousness of SARS-CoV-2 and the uncer-
tainty of human infection suddenly changed the functioning of
hospitals and led to a new way of organizing the activity, as well
as the setup of measures to protect the health of hospital
workers.4-7 In this context, the clinical and molecular pathology
laboratories, notably those receiving specimens from the respi-
ratory tract, were required to face up to the new constraints
associated with the COVID-19 pandemic.8
This study aimed to evaluate in Europe the consequences of
the COVID-19 pandemic on pathology laboratories that have a
strong activity in thoracic diseases for the period between 15
March and 31May 2020. Attention was given to (i) changes to
organization and the establishment of protectivemeasures, (ii)
the clinical,molecular and biobanking activities, (iii) the setting
up of research projects in the field of COVID-19 and the con-
tinuity of training programs for residents and pathologists, (iv)
the planned projects for improvement of the management of
these laboratories following the first wave of infection, and (v)
the number of staff memberswhowere potentially infected or
developed COVID-19.MATERIAL AND METHODS
Study oversight
On behalf of the Pulmonary Pathology Working Group of the
European Society of Pathology, a survey was sent to 712 https://doi.org/10.1016/j.esmoop.2020.100024pathologists, mainly experts in thoracic pathology, in several
European countries (https://www.esp-pathology.org/working-
groups/esp-working-groups/pulmonary-pathology.html). This
survey contained questions focused globally on the conse-
quences of the COVID-19 pandemic on the organization and
the activities of the pathology laboratories between 15
March and 31 May 2020 (Supplementary Table S1, available
at https://doi.org/10.1016/j.esmoop.2020.100024). The
different parts of the survey included questions on: (i) the
pre-existing or new setups for biosafety procedures, (ii)
the clinical diagnostic activity in the area of thoracic cellular
pathology, (iii) the molecular pathology applied to lung can-
cer samples, (iv) the collection of biospecimens for trans-
lational research purposes, (v) the development of research
focused on COVID-19, (vi) the organization of the work time
of staff members, (vii) the training and educational programs,
(viii) the different measures considered following the first
wave of the COVID-19 pandemic, and, (ix) information on the
SARS-CoV-2-infected or suspected-infected staff members
(Supplementary Table S1, available at https://doi.org/10.
1016/j.esmoop.2020.100024). This study was registered
with the ClinicalTrials.gov identifier, number NCT04476823.
Moreover, the study complied with the law of January 1978
(78-17) relating to computing, data, and freedom known as
‘computing and freedoms’ and with rules 2016/679 of the
European Parliament (of 25 May 2018) concerning the gen-
eral data protection regulation (GDPR; MR004). The study
was registered by the Nice University Hospital (R04-39) and
filed on the Health Data Hub website (7 July 2020) (www.
health-data-hub.fr/depot).Statistical analysis
All the data were collected and entered into an Excel® file.
Categorical data were determined as frequencies and per-
centages. Statistical comparisons were evaluated with the
paired and unpaired chi-square or Fisher’s exact tests whenVolume 6 - Issue 1 - 2021
P. Hofman et al. ESMO Openindicated. Quantitative data were determined as the mean,
standard deviation, range, and quartile; the paired and
unpaired Student’s t or Wilcoxon tests were used to
compare these data. All statistical analyses were two-sided
and generated with R-3.5.1 software.
RESULTS
A total of 53 out of 71 (75%) pathology laboratories from 42
cities of 18 European countries participated in the survey
(Supplementary Figure S1A, available at https://doi.org/10.
1016/j.esmoop.2020.100024). The number of participants
per country varied from 1 to 19 (Supplementary Figure S1B,
available at https://doi.org/10.1016/j.esmoop.2020.100024).
The COVID-19 incidence during this period in the partici-
pating countries had no impact on the number of ques-
tionnaires returned, as we had as many surveys returned
from countries with high COVID-19 incidence (mean ¼ 3
returned questionnaires; e.g. Italy, Spain, France) as in
countries with low COVID-19 incidence (mean ¼ 3 returned
questionnaires; e.g. Sweden, Germany, Finland). The main
data are shown in Figures 1-5.Pre-existing or new setups for biosafety procedures
Sample workflow from the clinical and surgical de-
partments to the pathology department and procedures
for handling biospecimens in the laboratory. The COVID-19
status of patients for whom cytological, biopsy, or surgical
specimens were taken was known before the handling of
the samples by the staff of the pathology laboratory in56.6%
54.7%
73.5%











Knowledge of COVID-19 infectious status 
before transfer  
Figure 1. Sample workflow from the clinical and surgical departments to the path
laboratory.
(A) Knowledge of the COVID-19 infectious status before the transfer to the laboratory,
(D) Class 2 biological safety cabinet (BSC-2) equipment in the room for gross macros
Volume 6 - Issue 1 - 202130/53 (56.6%), 29/53 (54.7%), and 39/53 (73.5%) cases,
respectively (Figure 1). Thirty out of 53 (56.6%) laboratories
did not have pneumatic tubes and received samples by
hospital couriers (Figure 1). Among the 23/53 (43.3%)
remaining laboratories, 3/23 (13%) stopped using pneu-
matic tubes and received the samples by hospital courier
only. Samples were sent to the laboratories in a triple
package (as recommended by international guidelines ac-
cording to UN 3373 and P650 norms) in 20/53 (37.7%)
cases and in usual packages in 33/53 (62.3%) of cases
(Figure 1). Ten out of 53 (18.8%) laboratories were equip-
ped with a class 2 biosafety cabinet (BSC-2) in the room for
gross macroscopy, which required handling of fresh tissue
and frozen sections (Figure 1). Forty-two out of 53 (79.2%)
laboratories had a BSC-2 for cytological samples, notably
for handling and processing of fresh body fluids such as
broncho-alveolar lavage (BAL) samples. The number of staff
members allowed to work at the same time in the gross
macroscopy room varied (from 2 to 16, median 2) or was
not regulated by a consistent rule in 18/52 (34.6%) of
cases.
Personal protective equipment. When handling tissue and
cytological samples, 24/53 (45.3%) and 29/53 (54.7%) of the
personnel (pathologists and technicians) wore a surgical or
filtering face piece class 2 (FFP2)/N95 mask, respectively.
Thirty-one out of 53 laboratories (58.5%) used one pair of
gloves while 22 (41.5%) used two pairs. Twenty out of 52
laboratories (38.5%) wore surgical caps and 10/51 (19.6%)
used surgical overshoes. The use of other personal protec-








D Availability of BSC-2 
Transport method
ology department and procedures for handling biospecimens in the pathology
according to the type of procedure. (B) Transport method. (C) Packaging method.
copy and frozen section.
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ESMO Open P. Hofman et al.The clinical diagnostic activity of thoracic cellular pathol-
ogy. The number of histological, cytological, and surgical
samples decreased significantly for the considered period of
analysis from 2019 to 2020 but was variable according to
the type of biospecimen (Figure 2). The most significant
decrease was recorded for the intraoperative frozen sec-
tions (Figure 2). The decrease in the number of surgical
interventions could explain, at least partially, the decrease
in the thoracic pathology activity, whereas the incidence of
severe lung cancer cases dramatically increased for the
same studied period (Supplementary Figure S2, available at
https://doi.org/10.1016/j.esmoop.2020.100024). Addition-
ally, the mean number of autopsies slightly decreased from
a mean of 27.47 (2019) to a mean of 25.29 (2020)
(Figure 2). Moreover, only 19/53 (35.8%) institutions carried
out autopsies on COVID-19-positive patients. Nine out of























Figure 2. Comparison of the clinical activity from 15 March to 31 May 2019 and f
Vertical axis, type of analysis; horizontal axis, log[adjusted odds ratio] (0 ¼ no effec
deviation), the area of each square is proportional to the sample size of analysis 2019
[OR], logarithm of the odds ratio (OR) for the linear regression model; SD, standard
4 https://doi.org/10.1016/j.esmoop.2020.100024Molecular pathology for lung cancer patients. Some mo-
lecular pathology analyses were maintained, in particular
for the next-generation sequencing (NGS) tests (Figure 3).
However, a significant decrease from 2019 to 2020 was
noted for the number of liquid biopsies (median decrease,
30.19%), the NGS analysis for clinical trials (median
decrease, 17.54%), specific polymerase chain reaction (PCR)
tests (median decrease, 14.06%), and the analyses using in
situ fluorescent hybridization (median decrease, 10.84%)
(Figure 3).
Collection of biospecimens for translational research pur-
poses. The amount of biobanking of tumor tissues and
liquid biopsies dropped from 2019 to 2020 (Figure 4). Only a
few laboratories [3/53 (5.6%)] actively collected samples
from COVID-19 patients (not shown). Twenty out of 53
(43.4%) pathology laboratories carried out or were associ-
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Figure 3. Comparison of the molecular pathology activity from 15 March to 31 May 2019 and from 15 March to 31 May 2020.
Vertical axis, type of analysis; horizontal axis, log[adjusted odds ratio] (0 ¼ no effect, <0 ¼ reduction in activity between 2019 and 2020); solid line: 2 (standard
deviation), the area of each square is proportional to the sample size of analysis 2019 and 2020; P value, P value for linear regression model adjusted to the center; log
[OR], logarithm of the odds ratio (OR) for the linear regression model; SD, standard deviation of the log[OR].
NGS, next-generation sequencing; PCR, polymerase chain reaction.
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Figure 4. Comparison of the biobanking activity between 15 March to 31 May 2019 and from 15 March to 31 May 2020.
Vertical axis. type of analysis; horizontal axis, log[adjusted odds ratio] (0 ¼ no effect, <0 ¼ reduction in activity between 2019 and 2020); solid line, 2 (standard
deviation), the area of each square is proportional to the sample size of analysis 2019 and 2020; P value, P value for linear regression model adjusted to the center; log
[OR]: logarithm of the odds ratio (OR) for the linear regression model; SD, standard deviation of the log[OR].
FFPE, formalin-fixed paraffin-embedded.
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ESMO Open P. Hofman et al.activity of the 23 pathology laboratories led (to date) to 71
manuscripts accepted for publication (median 3, range
1-10) in the area of COVID-19.
Organization of the staff members’ work time. The ma-
jority [47/53 (88.6%)] of pathology laboratories set up tel-
eworking for at least one of the occupational categories,
but mainly for the pathologists, the technicians, and the
residents (Figure 5). The mean percentage of teleworking
varied according to the occupational categories; notably, it
was 28.3% (range, 0%-80%), 32.8% (range, 0%-80%), and
40.7% (range, 0%-100%), for the pathologists, the techni-
cians, and the residents, respectively (Figure 5).
Training programs. Educational programs for residents and
junior pathologists were maintained in the majority of cases
[38/53 (71.7%)] using webinars (24.5%), digital pathology
training and/or virtual courses (20.7%), and other activities
(73.6%).
Different measures considered following the ‘first wave’ of
the COVID-19 pandemic. The survey included a free text
entry field to add information on different strategies to be
considered after the first wave of the COVID-19 crisis. The
questions focused notably on improvement of biosafety,
development of training, and the intent to develop specific
research into COVID-19 (Supplementary Table S1, available
at https://doi.org/10.1016/j.esmoop.2020.100024). Glob-
ally, most of the laboratories considered improving their
biosafety procedures [32/49 (65.3%)], and a few of them
aimed to optimize the rooms for gross macroscopy, notably
to set up a biosafety level 2 (BSL-2) environment and
maintain the PPE. Some laboratories [28/49 (57.1%)]
claimed that they would develop virtual training, but
without giving any detail. Finally, a few laboratories carried
out or participated in translational research projects on
COVID-19.
Information into the SARS-CoV-2-infected or suspected-
infected staff members. Of the personnel, 218/3368
(6.4%) and 136/3368 (4.9%) had fever or associated symp-
toms, respectively, which were suggestive of COVID-19. It is

















Figure 5. Mean percentage of teleworking according to the occupational
categories.
6 https://doi.org/10.1016/j.esmoop.2020.100024higher number of technicians (110) than pathologists (65). A
positive RT-PCR for SARS-CoV-2 was obtained in 64/777
(8.2%) of the tested personnel and 182/3368 (5.4%) staff
members were in quarantine. Those with COVID-19 (64/64)
were strongly suspected of having been infected outside of
the workplace (infection by a family member known to be
SARS-CoV-2-positive). No infection at the work site was
identified, neither due to an inter-individual nor due to
sample/aerosol contamination. Of the personnel, 547/3368
(16.2%) had a serological test for SARS-CoV-2 antibodies. A
positive serological test was declared for only 36/547 (6.6%)
of staff members.DISCUSSION
This study showed that the consequences of the COVID-19
pandemic in pathology laboratories in Europe were het-
erogeneous, notably for those in the field of thoracic
pathology. Consequences concerned: (i) the biosafety
measures and the introduction of changes to the organi-
zation of laboratory practices and (ii) the different activities
including clinical and molecular pathology diagnoses as well
as biobanking activities (Figure 6). This has been presented
according to the different countries, cities, and institutions.
The COVID-19 pandemic has a strong impact on clinical
and molecular pathology in oncology (Figure 6).9-11 Delays
due to COVID-19 had dramatic changes on the number of
underdiagnosed cancer cases and additional cancer deaths,
as recently reported by two modelling studies in
England.12,13 This is highlighted in the present study by a
substantial decrease in the activity in Italy, France, Spain,
and the UK, and to a lesser degree in some of the other
countries. Though the level of decline was not reported in
this study, it could be explained, at least partially, by a
decrease in the number of hospitalized patients with a
thoracic pathology (other than a COVID-19 associated dis-
ease) during this period. For example, some patients with
lung cancer seemed to have avoided hospitalization out of
fear of being infected with SARS-CoV-2 or the care of these
patients was delayed by the physicians.14,15 Moreover,
some cancer patients were assumed not to be treated
adequately due to extensive devotion of medical services to
COVID-19 patients. In addition, in certain institutions, the
staff members of pathology laboratories were reoriented to
work in the emergency or other clinical departments to take
part in the different activities against COVID-19 and to help
take care of COVID-19-positive patients. A European
decrease in the molecular pathology analyses for genomic
alterations in lung cancer was noted during the studied
period. This could be explained by the fact that molecular
biology testing needed more staff members on-site and less
social distancing between the personnel, which was
mandatory in certain laboratories. Moreover, during the
COVID-19 crisis, we assume that a minimum of molecular
testing (such as EGFR mutations and ALK rearrangement)
have been carried out as mandatory for the standard of
care. In addition, a lower number of patients being included
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Figure 6. The major consequences in the European thoracic pathology laboratories during the COVID-19 pandemic from 15 March to 31 May 2020.
P. Hofman et al. ESMO Opentargeted sequencing systems. Moreover, in the laboratories
performing liquid biopsies, the number of respective mo-
lecular analyses decreased, including the number of tar-
geted sequencing tests.
Sustaining clinical and molecular pathology during the
COVID-19 pandemic, notably to perform the different
diagnostic tests requested by the physicians for hospitalized
lung cancer patients could be challenging in the pathology
laboratories due to a possible reduced number of health-
care workers (HCWs).9,11,16,17 Thus, staff members may
become infected with SARS-CoV-2 (notably after viral
transmission among HCWs or from an external positive
COVID-19 individual) and the staff members who came in
contact with the infected HCW may be placed in quaran-
tine. This could lead to reduced ability to perform critical
steps of the molecular pathology analyses of cancer pa-
tients. In this context, to prevent the shutdown of clinical
and molecular pathology, it is critical to adopt a strategy
aimed at restricting the maximum number of personnel
inside the laboratory, but also to keep a safe distance be-
tween operators. Hence technicians and medical staff
should plan their daily routine based on the minimum
number of individuals required for each room. Moreover, it
is important to adopt as much as possible teleworking for all
professional categories. Senior consultants, medical stu-
dents, and residents should not be present in the laboratory
during the COVID-19 crisis. The present study showed that,
apart for some laboratories, most of them had a common
strategy to reduce the number of personnel working at the
same time in the same room, at least in the rooms dedi-
cated to macroscopy and preparation of frozen sections
with more than 80% of the laboratories having no more
than two staff members working at the same time in theseVolume 6 - Issue 1 - 2021rooms. Moreover, teleworking was set up in most of the
laboratories not only for the pathologists and the techni-
cians but also for other professional categories.
We tried to evaluate the number of HCWs in a large
number of European pathology laboratories who may have
been SARS-CoV-2 positive or had some suggestive clinical
symptom(s) of COVID-19 including fever. Thus, even if a
small number of staff members became infected, as
confirmed by a positive COVID-19 RT-PCR, more than 5% of
the staff members showed a strong suspicion of COVID-19
as they had suggestive symptoms of this disease. More-
over, the impact of these different symptoms and results on
the measures of quarantine was quite substantial since
around 4%-6% of the staff members were required to stay
at home due to a strong suspicion of COVID-19 or due to
contact with another COVID-19-positive staff member.
None of the cases of infection arose due to handling of
SARS-CoV-2-positive samples and for a few HCWs, infection
outside the work place was quite certainly due to infection
via family members. One major limitation of this study is
that the staff members were not regularly tested by RT-PCR
for SARS-CoV-2 and thus infection of HCWs due to contact
with asymptomatic subjects in the laboratory could not be
ruled out.
It is noteworthy that despite the rapid introduction of in-
ternational guidelines concerning the laboratory biosafety





march-26-2020), the different protective measures for pa-
thology laboratory HCWs were implemented in a variablehttps://doi.org/10.1016/j.esmoop.2020.100024 7
ESMO Open P. Hofman et al.fashion by the laboratories who participated in this study. One
explanation for this could be a lack of understanding and some
uncertainties of the contagiousness of the human samples
handled in the pathology laboratory in the COVID-19
context.18-21 The risk of infection of HCWs in the pathology
laboratory is certainlymuch lower than in clinical departments
(emergency and intensive care/reanimation units, pulmonol-
ogy and other departments), and possibly in virology labora-
tories, although the actual risk remains to be determined.22,23
The main risk in a pathology laboratory probably comes from
transmissionamongHCWsdue to thenon-complianceof social
distancing in the laboratory space.24At least in theory, the level
of contagiousness of human samples is certainly variable
depending on the nature and condition of the material (fresh,
frozen or fixed samples), yet until now no case of SARS-CoV-2
infection has been reported due to sample handling in a pa-
thology laboratory.25-27 However, specificmeasures need tobe
put in place to handle fresh thoracic tissue specimens, notably
during procedures using frozen sections and non-fixed cyto-
logical samples (such as BAL, pleural effusions, bronchial as-
pirates, fine needle aspirate material) and processing and
storage of frozen specimens. Thus, in the present study, it was
noteworthy thatmost of the laboratories did not have a BSC-2
in the room for macroscopic analysis for handling of fresh
tissue specimens and preparing frozen sections. Most of these
pathology laboratories were only equipped with chemical
hoods or with aspiration tables for gross macroscopy. Addi-
tionally, almost half of the HCWs working with fresh tissue
specimens wore a surgical mask only and not an FFP2/NP95
protective system. The use of other PPE (goggles, face shields,
surgical caps, etc.) varied from one laboratory to another. In-
ternational guidelines have recommendedabandoning theuse
of pneumatic tubes for tissue and cytological sample trans-






march-26-2020). However, only 13% (3/23) of the pathology
laboratories involved in this study stopped using pneumatic
tubes for sample transportation. It was not clear if the
remaining 20 laboratories knew the COVID-19 status of pa-
tients from whom samples were received through pneumatic
tubes. Interestingly, the COVID-19 status of the patients’
samples (fixed and/or fresh tissue and cytological samples) by
the HCWs who handled samples was known in only around
50% of the laboratories. Thus, the biosafety measures and
biospecimen handling need to be increased, adapted to the
latest scientific data, and standardized and implemented (re-
iterative cycle). These measures are required anyhow when
handling fresh frozen tissue and unfixed liquid/cytological
specimens in pathology laboratories to prevent infection by
pathogens certainly more contagious for HCWs than SARS-
CoV-2 (e.g. mycobacteria, human immunodeficiency virus,
hepatitis B and C viruses, etc.). It is necessary to take into
consideration that these procedures are associated with
increased costs for the laboratories.8 https://doi.org/10.1016/j.esmoop.2020.100024One of the consequences of the COVID-19 crisis was the
absolute necessity to develop virtual educational programs,
notably for residents and junior pathologists (digital pa-
thology training, virtual courses, webinars, etc.).28-30 How-
ever, the results of the present survey showed that only
around 25% of the laboratories set up these programs,
highlighting the urgent need to become aware of the utility
of these different tools. In addition, some information, in
particular concerning the biosafety procedures to follow in
a pathology laboratory should be established through vir-
tual training, and this was the case in the present study for
no more than 25% of the laboratories.
One of the more important negative consequences of the
COVID-19 pandemic occurred in the biobanking field for
translational research purposes, notably for the collection
of samples from lung cancer patients (Figure 6).31,32 Bio-
banking in the field of thoracic pathology decreased sub-
stantially or was shut down in most of the pathology
laboratories participating in this survey. Biobanking has
been extremely important to provide material to solve the
COVID-19 pathogenesis and a seminal contribution of pa-
thology. Thus, pathologists should be strengthened to
assure the continuity of the COVID-19 biobanking.33
Conversely, a number of the pathology laboratories
included in the present work had the possibility to partici-
pate in and/or lead research projects into COVID-19.33-37
Thus, at the time of submission of this study, 71 manu-
scripts were published or submitted for publication in as-
sociation with one or several of these pathology
laboratories, which was a fruitful consequence occurring in
only a short period of time.
Our study has a couple of limitations. Not all European
countries were included. There is heterogeneity between
the laboratories located in different countries, mostly with
regard to the molecular pathology activity and the caseload
(academic versus community hospitals). Because the survey
herein was designed to address the measures taken from 15
March to 31 May 2020, the results of the current study
might not apply to the later periods of the pandemic.
Finally, it would be of interest to see if the different COVID-
19 incidences according to the countries participating in this
survey have a different impact on the pathology labora-
tories’ activity.38 However, it was difficult to have regional
incidence data inside each country (e.g. north versus south)
given the scattered nature of the laboratories.
While Europe was the epicenter of the COVID-19
pandemic between February and May 2020, subsequently,
the number of infected patients who were hospitalized
decreased progressively. Thus, at the time of submission of
this study, the aim was to sustain and/or to reinforce the
different protective measures so far implemented, at least
partially. Some of these procedures are costly, constrain the
activity of HCWs, and modify the organization of the daily
practice of the pathology laboratories. In this regard, the
following questions may be asked: (i) is it possible to again
use pneumatic tubes for sample transportation, (ii) can
pathologists again use multi-head microscopes for collective
observation of slides, (iii) should all the HCWs keep wearingVolume 6 - Issue 1 - 2021
P. Hofman et al. ESMO Openmasks when working in all the sectors of the laboratory, (iv)
should teleworking become permanently established as a
way of working, irrespective of the professional category, (v)
is it now mandatory to use a BSC-2 for gross macroscopy of
fresh tissue samples and frozen sections, in association with
a chemical hood with a HEPA filter for handling formalin-
fixed specimens, and (vi) is it always critical to know the
COVID-19 status of patients before receiving tissue and
cytological samples, notably fresh samples and before
frozen section and/or biobanking procedures? The results of
the present survey demonstrated that depending on the
pathology laboratory participating in this study, the strategy
to adopt still varied, despite the current international
guidelines.39
Whatever the adopted strategy, the COVID-19 pandemic
sparked the improvement of the biosafety procedures now
in place in many European pathology laboratories partici-
pating in this study and to the re-evaluation of the orga-
nization of the work. It is noteworthy that although many
pathology laboratories were not optimally equipped, the
rate of infection among HCWs was low and COVID-19-
positive staff members were infected outside of the work-
place. This highlights that major prevention measures such
as wearing surgical or FFP2/N95 masks and adopting a safe
distance between operators were certainly effective in
containing/reducing infection between staff members. We
strongly believe that most of the different actions that have
been set up must now be sustained and that the pathology
laboratories need to rapidly adapt their working day to
change the organization, notably in the event of futures
COVID-19 waves.40
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